Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897043380> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2897043380 endingPage "314" @default.
- W2897043380 startingPage "306" @default.
- W2897043380 abstract "Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate-to-severe psoriasis.To evaluate the efficacy and safety of brodalumab through week 52 in patients who had inadequate responses to ustekinumab.A subgroup analysis of the phase III AMAGINE-2/-3 double-blind randomized controlled trials was performed. Participants were aged 18-75 years and had a Psoriasis Area and Severity Index (PASI) ≥ 12, static Physician's Global Assessment score ≥ 3 and involvement of ≥ 10% body surface area. The studies were registered at ClinicalTrials.gov: AMAGINE-2, NCT01708603; AMAGINE-3, NCT01708629.At baseline, patients with or without prior biologic experience who had an adequate response at week 16 on ustekinumab or brodalumab had lower rates of involved body surface area, PASI, prior biologic use, psoriatic arthritis and body mass index than patients who experienced inadequate response at or after week 16. Among patients who experienced inadequate response to ustekinumab, those rescued with brodalumab had PASI ≥ 75%, ≥ 90% and 100% improvement response rates of 72·6%, 58·1% and 36·3%, respectively, at week 52 compared with 61·7%, 25·5% and 5·4%, respectively, in patients who continued ustekinumab. Exposure-adjusted rates of treatment-emergent adverse events were similar among patients rescued with brodalumab (377·3 adverse events per 100 patient-years) and those who remained on ustekinumab (389·9 adverse events per 100 patient-years).Among patients who experienced inadequate responses to ustekinumab, rescue with brodalumab improved skin clearance outcomes compared with continuing ustekinumab." @default.
- W2897043380 created "2018-10-26" @default.
- W2897043380 creator A5000478173 @default.
- W2897043380 creator A5018781671 @default.
- W2897043380 creator A5033903141 @default.
- W2897043380 creator A5035384537 @default.
- W2897043380 creator A5038505651 @default.
- W2897043380 creator A5038764284 @default.
- W2897043380 creator A5061849637 @default.
- W2897043380 creator A5070281210 @default.
- W2897043380 creator A5080237247 @default.
- W2897043380 date "2018-12-27" @default.
- W2897043380 modified "2023-10-05" @default.
- W2897043380 title "Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase <scp>III</scp> trials" @default.
- W2897043380 cites W1993273784 @default.
- W2897043380 cites W2021018799 @default.
- W2897043380 cites W2121900420 @default.
- W2897043380 cites W2276035339 @default.
- W2897043380 cites W2326643498 @default.
- W2897043380 cites W2518865922 @default.
- W2897043380 cites W2697574135 @default.
- W2897043380 cites W2730335164 @default.
- W2897043380 cites W2735708380 @default.
- W2897043380 doi "https://doi.org/10.1111/bjd.17318" @default.
- W2897043380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30328108" @default.
- W2897043380 hasPublicationYear "2018" @default.
- W2897043380 type Work @default.
- W2897043380 sameAs 2897043380 @default.
- W2897043380 citedByCount "23" @default.
- W2897043380 countsByYear W28970433802019 @default.
- W2897043380 countsByYear W28970433802020 @default.
- W2897043380 countsByYear W28970433802021 @default.
- W2897043380 countsByYear W28970433802022 @default.
- W2897043380 countsByYear W28970433802023 @default.
- W2897043380 crossrefType "journal-article" @default.
- W2897043380 hasAuthorship W2897043380A5000478173 @default.
- W2897043380 hasAuthorship W2897043380A5018781671 @default.
- W2897043380 hasAuthorship W2897043380A5033903141 @default.
- W2897043380 hasAuthorship W2897043380A5035384537 @default.
- W2897043380 hasAuthorship W2897043380A5038505651 @default.
- W2897043380 hasAuthorship W2897043380A5038764284 @default.
- W2897043380 hasAuthorship W2897043380A5061849637 @default.
- W2897043380 hasAuthorship W2897043380A5070281210 @default.
- W2897043380 hasAuthorship W2897043380A5080237247 @default.
- W2897043380 hasConcept C126322002 @default.
- W2897043380 hasConcept C16005928 @default.
- W2897043380 hasConcept C168563851 @default.
- W2897043380 hasConcept C187960798 @default.
- W2897043380 hasConcept C197934379 @default.
- W2897043380 hasConcept C2776260265 @default.
- W2897043380 hasConcept C2777011040 @default.
- W2897043380 hasConcept C2777501473 @default.
- W2897043380 hasConcept C2778975655 @default.
- W2897043380 hasConcept C2779134260 @default.
- W2897043380 hasConcept C2780132546 @default.
- W2897043380 hasConcept C2780564577 @default.
- W2897043380 hasConcept C71924100 @default.
- W2897043380 hasConcept C95190672 @default.
- W2897043380 hasConceptScore W2897043380C126322002 @default.
- W2897043380 hasConceptScore W2897043380C16005928 @default.
- W2897043380 hasConceptScore W2897043380C168563851 @default.
- W2897043380 hasConceptScore W2897043380C187960798 @default.
- W2897043380 hasConceptScore W2897043380C197934379 @default.
- W2897043380 hasConceptScore W2897043380C2776260265 @default.
- W2897043380 hasConceptScore W2897043380C2777011040 @default.
- W2897043380 hasConceptScore W2897043380C2777501473 @default.
- W2897043380 hasConceptScore W2897043380C2778975655 @default.
- W2897043380 hasConceptScore W2897043380C2779134260 @default.
- W2897043380 hasConceptScore W2897043380C2780132546 @default.
- W2897043380 hasConceptScore W2897043380C2780564577 @default.
- W2897043380 hasConceptScore W2897043380C71924100 @default.
- W2897043380 hasConceptScore W2897043380C95190672 @default.
- W2897043380 hasIssue "2" @default.
- W2897043380 hasLocation W28970433801 @default.
- W2897043380 hasLocation W28970433802 @default.
- W2897043380 hasOpenAccess W2897043380 @default.
- W2897043380 hasPrimaryLocation W28970433801 @default.
- W2897043380 hasRelatedWork W107859310 @default.
- W2897043380 hasRelatedWork W1998836331 @default.
- W2897043380 hasRelatedWork W2032788879 @default.
- W2897043380 hasRelatedWork W2235471063 @default.
- W2897043380 hasRelatedWork W2288445425 @default.
- W2897043380 hasRelatedWork W2341013428 @default.
- W2897043380 hasRelatedWork W2415983218 @default.
- W2897043380 hasRelatedWork W2745529784 @default.
- W2897043380 hasRelatedWork W3176363967 @default.
- W2897043380 hasRelatedWork W4246448086 @default.
- W2897043380 hasVolume "180" @default.
- W2897043380 isParatext "false" @default.
- W2897043380 isRetracted "false" @default.
- W2897043380 magId "2897043380" @default.
- W2897043380 workType "article" @default.